{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T07:44:40Z","timestamp":1761291880117,"version":"build-2065373602"},"reference-count":33,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2002,6,12]],"date-time":"2002-06-12T00:00:00Z","timestamp":1023840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>An intensified treatment regimen for previously untreated Stage III and IV resectable oral cavity, oropharyngeal, or hypopharyngeal squamous cell carcinoma was analyzed to assess disease control, patient compliance, and toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Forty three patients with previously untreated, advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, or hypopharynx were enrolled in a prospective Phase II institutional clinical trial at a tertiary care comprehensive cancer center. This regimen was a continuum of multimodal treatment in a contracted time interval. It included preoperative slightly accelerated hyperfractionated radiotherapy with concurrent cisplatin, followed immediately with surgery and intraoperative radiotherapy, and completed with early postoperative weekly paclitaxel (beginning on Day 6 after surgery), two additional cisplatin cycles, and concurrent once daily radiotherapy beginning on Day 28 after surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The current trial was designed to reduce the toxicity of the systemic therapy while maintaining or improving locoregional\/distant disease control and patient compliance. There were 43 patients enrolled, and the range of time at risk was 2.6 to 24.7 months (median, 14.6 months). Of the 43 registered patients, 43 were evaluable. The locoregional (100%) and systemic (93%) disease control rates were excellent, with low rates of patient noncompliance (21%) and reduced levels of toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>An intensive treatment regimen that improves disease control and treatment compliance is clearly feasible for this patient population. Future plans include modifications to continue to reduce toxicity and expansion to a multi\u2010center Phase II trial to determine if the single institutional results can be duplicated. Cancer 2002;94:3169\u201378. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10571<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10571","type":"journal-article","created":{"date-parts":[[2002,10,6]],"date-time":"2002-10-06T08:29:56Z","timestamp":1033892996000},"page":"3169-3178","source":"Crossref","is-referenced-by-count":16,"title":["Multimodal intensification therapy for previously untreated advanced resectable squamous cell carcinoma of the oral cavity, oropharynx, or hypopharynx"],"prefix":"10.1002","volume":"94","author":[{"given":"David E.","family":"Schuller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Grecula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris A.","family":"Rhoades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra A.","family":"Orr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donn C.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Merz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,6,12]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_6_2_2","DOI":"10.3322\/canjclin.49.1.8"},{"doi-asserted-by":"publisher","key":"e_1_2_6_3_2","DOI":"10.1016\/0360-3016(92)90642-U"},{"doi-asserted-by":"publisher","key":"e_1_2_6_4_2","DOI":"10.1288\/00005537-198008000-00002"},{"doi-asserted-by":"publisher","key":"e_1_2_6_5_2","DOI":"10.1007\/978-1-4613-1499-8_11"},{"doi-asserted-by":"publisher","key":"e_1_2_6_6_2","DOI":"10.1001\/archotol.1991.01870170044011"},{"doi-asserted-by":"publisher","key":"e_1_2_6_7_2","DOI":"10.1288\/00005537-198811000-00011"},{"key":"e_1_2_6_8_2","first-page":"285","article-title":"Postoperative adjuvant treatment of advanced head and neck cancer: Wayne State University experience and Southwest Oncology Group Feasibility Trial","volume":"12","author":"Kish J","year":"1993","journal-title":"Am Soc Clin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_6_9_2","DOI":"10.1002\/1097-0142(19870801)60:3<301::AID-CNCR2820600306>3.0.CO;2-V"},{"key":"e_1_2_6_10_2","first-page":"1781","article-title":"Combined\u2010modality therapy for head and neck cancer","volume":"11","author":"Fu K","year":"1997","journal-title":"Oncology."},{"key":"e_1_2_6_11_2","first-page":"1310","article-title":"Chemo\u2010radiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099 (SWOG 8892, RTOG 8817, ECOG 2388)","volume":"16","author":"Al\u2010Sarraf M","year":"1998","journal-title":"J Clin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_6_12_2","DOI":"10.1016\/S0360-3016(96)00614-1"},{"doi-asserted-by":"publisher","key":"e_1_2_6_13_2","DOI":"10.1093\/jnci\/88.9.583"},{"key":"e_1_2_6_14_2","first-page":"411a","article-title":"An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"19","author":"Adelstein DJ","year":"2000","journal-title":"Proc ASCO."},{"key":"e_1_2_6_15_2","first-page":"2272","article-title":"Superiority of five year survival with chemo\u2010radiotherapy (CT\u2010RT) vs radiotherapy in patients (Pts) with locally advanced nasopharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) Phase III study: final report","volume":"20","author":"Al\u2010Sarraf M","year":"2001","journal-title":"Proc ASCO."},{"doi-asserted-by":"publisher","key":"e_1_2_6_16_2","DOI":"10.1016\/S0196-0709(96)90016-2"},{"doi-asserted-by":"publisher","key":"e_1_2_6_17_2","DOI":"10.1159\/000061187"},{"doi-asserted-by":"publisher","key":"e_1_2_6_18_2","DOI":"10.1016\/S0360-3016(01)01567-X"},{"doi-asserted-by":"publisher","key":"e_1_2_6_19_2","DOI":"10.1001\/archotol.1997.01900020013002"},{"doi-asserted-by":"publisher","key":"e_1_2_6_20_2","DOI":"10.1001\/archotol.125.12.1313"},{"doi-asserted-by":"publisher","key":"e_1_2_6_21_2","DOI":"10.1002\/1097-0142(20001215)89:12<2587::AID-CNCR11>3.0.CO;2-R"},{"doi-asserted-by":"publisher","key":"e_1_2_6_22_2","DOI":"10.1081\/CNV-100000147"},{"doi-asserted-by":"publisher","key":"e_1_2_6_23_2","DOI":"10.1016\/0360-3016(95)00028-W"},{"doi-asserted-by":"publisher","key":"e_1_2_6_24_2","DOI":"10.1016\/0360-3016(84)90408-5"},{"doi-asserted-by":"publisher","key":"e_1_2_6_25_2","DOI":"10.1200\/JCO.2000.18.7.1458"},{"doi-asserted-by":"publisher","key":"e_1_2_6_26_2","DOI":"10.1016\/0360-3016(95)00525-4"},{"doi-asserted-by":"publisher","key":"e_1_2_6_27_2","DOI":"10.1200\/JCO.1998.16.4.1318"},{"doi-asserted-by":"publisher","key":"e_1_2_6_28_2","DOI":"10.1200\/JCO.2001.19.7.1961"},{"doi-asserted-by":"publisher","key":"e_1_2_6_29_2","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<876::AID-CNCR19>3.0.CO;2-Y"},{"doi-asserted-by":"publisher","key":"e_1_2_6_30_2","DOI":"10.1056\/NEJM199806183382503"},{"doi-asserted-by":"publisher","key":"e_1_2_6_31_2","DOI":"10.1093\/jnci\/91.24.2081"},{"doi-asserted-by":"publisher","key":"e_1_2_6_32_2","DOI":"10.1016\/S0360-3016(01)01825-9"},{"doi-asserted-by":"publisher","key":"e_1_2_6_33_2","DOI":"10.1288\/00005537-198811000-00011"},{"doi-asserted-by":"publisher","key":"e_1_2_6_34_2","DOI":"10.1177\/000348947508400616"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10571","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:20:04Z","timestamp":1760296804000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,6,15]]}},"alternative-id":["10.1002\/cncr.10571"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10571","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2002,6,12]]}}}